ClinicalTrials.gg
CompletedNCT00908232SEQUENTIALUpdated Jan 15, 2015Results posted

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

A Phase 2 interventional study of Cyclophosphamide and Bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag International NV. Completed at 43 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-15.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
37th of 267
163 · median 41
Started
2008
with 21 others
Phase 2
137 of 271
6 open now
Registered
116th of 271
by date
Lead sponsor
5 of 271
Janssen-Cilag International NV

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 37th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 137 in phase 2, and was the 116th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4 initial cycles of treatment with VD. Multiple myeloma is the second most common cancer of the blood. Bortezomib disrupts the life cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.

Read the detailed description

It has been shown that quality of response corresponds with clinical benefit. Stable disease is not regarded as a satisfactory result of therapy for relapsed and refractory multiple myeloma. However, there is no consensus if, when and how treatment should be continued or changed in the case of stable disease.

There are different strategies of achieving an optimal quality of response in relapsed and refractory multiple myeloma. One is to treat for a longer duration with one regimen. The alternative path can be a sequential approach adding another agent to the initial regimen depending on the outcome of therapy after a defined treatment period. These two principles will be evaluated in the present study.

Both Cyclophosphamide and Lenalidomide have proven to be efficacious in multiple myeloma and combinations of both agents with bortezomib and Dexamethasone have been shown to be active and tolerable.

In this study patients with relapsed/progressive or refractory multiple myeloma will start treatment with bortezomiib and Dexamethasone. Response will be evaluated after four cycles. Patients with complete, very good partial response or partial response will continue treatment as initiated. Patients with stable disease will either continue treatment with the bortezomib/Dexamethasone combination for another four cycles or will receive Cyclophosphamide or Lenalidomide as an additional third agent for another four cycles.

Patients with multiple myeloma that are refractory to or have relapsed/progressed after primary treatment for multiple myeloma will be enrolled in the study. All patients will receive a combination of bortezomib plus dexamethasone for a total of four cycles. Based on the response to this treatment, further study treatment is customized. Patients with a complete, a very good partial or a partial response will continue to receive bortezomib and Dexamethasone for a maximum additional four cycles, to an overall maximum of eight cycles. Patients achieving stable disease, as defined by International Myeloma Working Group 2006 (IMWG 2006) response criteria, will undergo a central randomisation to continue treatment with VD or VD plus cyclophosphamide or VD plus lenalidomide. Patients with progressive disease will go off study treatment. After randomisation, patients will receive therapy for up to four additional treatment cycles, to an overall maximum of eight cycles. Each cycle will consist of three weeks treatment. There will be a long-term follow-up period with monthly visits until relapse or progressive disease. Thereafter follow-up for survival will be continued by at least a phone call every other month. This will be performed for all patients until the last patient was treated and followed up for 1 year.

Safety will be assessed by the monitoring of adverse events, physical examination (including neurological/peripheral neurological examinations), pulmonary examinations, vital signs measurements, and clinical laboratory tests.

Patients will be treated in a 3-week cycle, up to a maximum of 8 cycles bortezomib 1.3 mg/m2 will be administered on day 1, 4, 8 and 11 as i.v. bolus infusion.

Dexamethasone 20 mg po will be administered on days 1, 2, 4, 5, 8, 9, 11, 12. Dexamethasone will be administered as 2 tables of 8 mg plus 1 tablet of 4 mg Cyclophosphamide 500 mg po will be administered as 10 tablets of 50 mg on day 1, 8, 15 Lenalidomide will be administered as once daily 10 mg tablet from day 1 to 14

03

Conditions studied

  • Multiple Myeloma

Keywords

  • multiple myeloma
  • bortezomib
  • hematology
  • bone marrow cancer
  • immunoglobulin
  • refractory
  • progression
  • dexamethasone
  • lenalidomide
  • cyclophosphamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has /progressed or is refractory for multiple myeloma following 1
  • Measurable secretory multiple myeloma: for secretory multiple myeloma is defined by at least one of the following measurements: serum monoclonal protein greater than or equal to 1 g/dl (> 10 gm/l) [10g/l], urine M-protein of ≥200 mg/24 hours
  • Patient has a performance status of ≥ 60
  • Patient has a estimated at screening of at least 6 months
  • Patient fulfills defined pretreatment laboratory requirements at and within 14 days before baseline

Exclusion criteria

Exclusion Criteria:

  • Patient received more than 1 for multiple myeloma
  • Patient has known allergy or to bortezomib, Dexamethasone and/or Cyclophosphamide and/or Lenalidomide or any of the constituent compounds such as boron, mannitol, or lactose
  • Patient has oligosecretory or non-secretory multiple myeloma
  • Patient received nitrosoureas or any other chemotherapy (including thalidomide), clarithromycin, interferon within 6 weeks before enrolment. Note: subjects can have received thalidomide or interferon as maintenance therapy, according to local standard of care
  • Patient received (> 10 mg/day prednisone or equivalent) within 3 weeks before enrolment. Note: subjects can have received steroids (dexamethasone or equivalent) as maintenance therapy according to local standard of care. In addition, subjects can have received a cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy within 3 weeks prior to study entry.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Stable Disease: VD

    Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8

    Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Stable Disease: VDC

    Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8

    Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Stable Disease: VDL

    Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8

    Drug: Bortezomib · Drug: Dexamethasone · Drug: Lenalidomide

  • Experimental
    Complete to Partial Response: VD

    Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8

    Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • 500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles

  • 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8

  • 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

  • 10 mg orally daily, days 1-14 for cycles 5 to 8

06

What researchers measure

Primary outcomes

  1. Overall Best Confirmed Response

    Overall Best Confirmed Response is the best Overall Response Rate with borezomib-dexamathasone (+/-cyclophosphamide or lenalidomide) recorded between baseline and end of treatment. Response was assessed using the International Myeloma working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.

    Time frame: Prior to treatment at day 1 of each cycle and at the end of treatment (day 21 of cycle 8), up to 168 days

Secondary outcomes

  1. Median Time to First Confirmed Response

    Time from start of treatment to the date of the first documentation of a confirmed response. Estimated using the Kaplan-Meier method. Response was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.

    Time frame: At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR), up to 168 days

  2. Progression Free Survival

    Time from start of treatment to date of disease progression, relapse from CR or death. Estimated using the kaplan-meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate.

    Time frame: At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR). Median Follow-Up of 16.9 months

  3. Time to Progression

    Is calculated as the time from start of treatment to the date of the first observation of disease progression or relapse from CR. Deaths owing to causes other than progression not counted, but censored. Subjects who withdraw from the study or die will be censored at the time of last disease assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).

    Time frame: At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR), Median Follow-up of 16.9 months

  4. One Year Survival

    Percent Probability of Survival at 1 year from the start of treatment, estimated using Kaplan-Meier analysis.

    Time frame: At each visit from baseline to end of treatment. After treatment, monthly visit until progression or relapse or until the start of alternative MMY therapy, up to 1 year

  5. Overall Survival

    Is defined as the time interval from start of treatment to the date of death due to any cause. In the absence of confirmation of death (including subjects lost to follow-up), survival time will be censored at the last date the subject is known to be alive

    Time frame: At each visit from baseline to end of treatment. After treatment, monthly visit until progression or relapse or until the start of alternative MMY therapy. Further follow up by monthly phone call until the last patient was treated and followed for 1 year

07

Results

Posted Jun 8, 2012
Limitations and caveats
The response rate of bortezomib in combination with dexamethasone after 4 cycles was much higher than originally assumed. Therefore the sample size of the randomized groups is too small for further statistical analysis.

Participant flow

Cycle 1 to 4
Participant flow — Cycle 1 to 4
MilestoneCycle 1 to 4: Bortezomib + Dexamethasone (VD)Stable Disease: Bortezomib + Dexamethasone (VD)SD: Bortezomib+Dexamethasone+Cyclophosphamide (VDC)SD: Bortezomib+Dexamethasone+Lenalidomide (VDR)
Started163000
Completed135000
Not completed28000
Withdrew: Death5000
Withdrew: Withdrawal by subject4000
Withdrew: Progressive disease6000
Withdrew: Adverse event12000
Withdrew: Other1000
Randomization (Cycle 5) to Cycle 8
Participant flow — Randomization (Cycle 5) to Cycle 8
MilestoneCycle 1 to 4: Bortezomib + Dexamethasone (VD)Stable Disease: Bortezomib + Dexamethasone (VD)SD: Bortezomib+Dexamethasone+Cyclophosphamide (VDC)SD: Bortezomib+Dexamethasone+Lenalidomide (VDR)
Started98784
Completed63474
Not completed35310
Withdrew: Complete response/partial response1000
Withdrew: Progressive disease5000
Withdrew: Death2000
Withdrew: Withdrawal by subject4010
Withdrew: Adverse event17200
Withdrew: Physician decision2000
Withdrew: Other3100
Withdrew: Protocol violation1000

Outcome measures

PrimaryOverall Best Confirmed Response

Overall Best Confirmed Response is the best Overall Response Rate with borezomib-dexamathasone (+/-cyclophosphamide or lenalidomide) recorded between baseline and end of treatment. Response was assessed using the International Myeloma working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.

Time frame:
Prior to treatment at day 1 of each cycle and at the end of treatment (day 21 of cycle 8), up to 168 days
Reported as:
Number · number of participants
Overall Best Confirmed Response
number of participantsComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
Overall Best Confirmed Response1016
SecondaryMedian Time to First Confirmed Response

Time from start of treatment to the date of the first documentation of a confirmed response. Estimated using the Kaplan-Meier method. Response was assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria and validated by an Independent Monitoring Committee.

Time frame:
At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR), up to 168 days
Reported as:
Median · days
Median Time to First Confirmed Response
daysComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
Median Time to First Confirmed Response43.0 (43.0 to 58.0)NA (152.0 to NA)
SecondaryProgression Free Survival

Time from start of treatment to date of disease progression, relapse from CR or death. Estimated using the kaplan-meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate.

Time frame:
At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR). Median Follow-Up of 16.9 months
Reported as:
Median · days
Progression Free Survival
daysComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
Progression Free Survival311.0 (224.0 to 424.0)214.0 (198.0 to 234.0)
SecondaryTime to Progression

Is calculated as the time from start of treatment to the date of the first observation of disease progression or relapse from CR. Deaths owing to causes other than progression not counted, but censored. Subjects who withdraw from the study or die will be censored at the time of last disease assessment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).

Time frame:
At Day 1 of each treatment cycle, at the End of Treatment visit until there is evidence of Progressive Disease or relapse from Complete Response (CR), Median Follow-up of 16.9 months
Reported as:
Median · days
Time to Progression
daysComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
Time to Progression366.0 (281.0 to 475.0)214.0 (198.0 to 234.0)
SecondaryOne Year Survival

Percent Probability of Survival at 1 year from the start of treatment, estimated using Kaplan-Meier analysis.

Time frame:
At each visit from baseline to end of treatment. After treatment, monthly visit until progression or relapse or until the start of alternative MMY therapy, up to 1 year
Reported as:
Number · percent probability
One Year Survival
percent probabilityComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
One Year Survival80 (73 to 87)89 (62 to 97)
SecondaryOverall Survival

Is defined as the time interval from start of treatment to the date of death due to any cause. In the absence of confirmation of death (including subjects lost to follow-up), survival time will be censored at the last date the subject is known to be alive

Time frame:
At each visit from baseline to end of treatment. After treatment, monthly visit until progression or relapse or until the start of alternative MMY therapy. Further follow up by monthly phone call until the last patient was treated and followed for 1 year
Reported as:
Median · days
Overall Survival
daysComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
Overall SurvivalNA (888.0 to NA)NA (982.0 to NA)

Adverse events

Collected over From signing of informed consent until 30 days after the last dose of study medication (approximately 7 months) or longer if considered related to study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Complete to Partial Response: Bortezomib + Dexamethasone—59/144 (41%)137/144 (95.1%)
Stable Disease After 4 Cycles: VD, VDC, VDL—6/19 (31.6%)19/19 (100%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
PneumoniaInfections and infestations9/1440/19
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1441/19
Deep Vein ThrombosisVascular disorders0/1441/19
Cardiac FailureCardiac disorders3/1441/19
PyrexiaGeneral disorders3/1441/19
Oedema PeripheralGeneral disorders2/1441/19
Lower Respiratory Tract InfectionInfections and infestations3/1441/19
BronchopneumoniaInfections and infestations1/1441/19
Hepatitis BInfections and infestations0/1441/19
ThrombocytopeniaBlood and lymphatic system disorders6/1440/19
Most frequent other events
Showing 10 of 94
Most frequent other events
EventComplete to Partial Response: Bortezomib + DexamethasoneStable Disease After 4 Cycles: VD, VDC, VDL
ThrombocytopeniaBlood and lymphatic system disorders52/1448/19
AnaemiaBlood and lymphatic system disorders29/1446/19
ConstipationGastrointestinal disorders45/1445/19
DiarrhoeaGastrointestinal disorders45/1445/19
Oedema PeripheralGeneral disorders38/1445/19
FatigueGeneral disorders37/1440/19
AstheniaGeneral disorders29/1444/19
PyrexiaGeneral disorders15/1444/19
Peripheral Sensory NeuropathyNervous system disorders29/1444/19
NeuralgiaNervous system disorders22/1444/19

Baseline characteristics

modified Intent to Treat Population consisting of all 163 participants with at least 1 dose and 1 post baseline efficacy assessment.: Complete and Partial Responders (non-randomized), n=144. Stable Disease (randomized to VD, VDC, and VDL), n=19.

Age, Continuous
Age, Continuous(years)All Study Participants
Mean63.7 ± 11.04
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female77
Male86
Region of Enrollment
Region of Enrollment(participants)All Study Participants
France20
Germany15
Greece23
Hungary2
Lithuania9
Poland19
Serbia15
Spain20
Turkey19
United Kingdom21
08

Study locations

43 sites
  • Bordeaux, France
  • Le Mans Cedex 2, France
  • Lille Cedex, France
  • Tours Cedex 9, France
  • Duisburg, Germany
  • Essen, Germany
  • Frankfurt An Der Oder, Germany
  • Leipzig, Germany
  • München, Germany
  • Mÿnchen, Germany
  • Oldenburg, Germany
  • Ulm, Germany
  • Athens, Greece
  • Patra, Greece
  • Budapest, Hungary
  • Debrecen, Hungary
  • Miskolc, Hungary
  • Nyiregyhaza, Hungary
  • Szeged, Hungary
  • Kaunas, Lithuania
  • Klaipeda, Lithuania
  • Vilnius Lt, Lithuania
  • Bialystok, Poland
  • Katowice, Poland
  • Kraków, Poland
  • Lodz, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Belgrade, Serbia
  • Nis, Serbia
  • Novi Sad, Serbia
  • Sremska Kamenica, Serbia
  • Barcelona, Spain
  • Madrid, Spain
  • Toledo, Spain
  • Valencia, Spain
  • Ankara, Turkey
  • Istambul, Turkey
  • Istanbul, Turkey
  • Izmir, Turkey
  • Bath, United Kingdom
  • Edinburgh, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan;100(1):100-6. doi: 10.3324/haematol.2014.112037. Epub 2014 Sep 26. PubMed 25261096 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2009
First posted
May 25, 2009
Start
May 2008
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Jun 8, 2012
Last update
Jan 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00908232
Responsible party
Sponsor
First posted
May 25, 2009
Start date
May 2008
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jun 8, 2012
Last update
Jan 15, 2015

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Dexamethasone

Start the discussion